<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02933983</url>
  </required_header>
  <id_info>
    <org_study_id>B300201524257</org_study_id>
    <nct_id>NCT02933983</nct_id>
  </id_info>
  <brief_title>Microbiota Upper Respiratory Tract</brief_title>
  <acronym>ProCure</acronym>
  <official_title>Study of the Microbiota and the Potential of Probiotics for Chronic Rhinosinusitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Antwerp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate whether the microbiota in the upper respiratory tract
      (URT) (nose, nasopharynx and sinuses) of chronic rhinosinusitis (CRS) patients is disturbed
      compared to healthy individuals. Therefore, bacterial DNA from swabs, aspirates and tissue
      will be isolated via commercially available DNA extraction kits, followed by Illumina MiSeq
      sequencing in order to identify the bacterial species present in these samples. Special
      attention will go to microbial species that are overrepresented in the healthy populations as
      potential health promoting microbes (i.e. probiotics). A better understanding of the URT
      microbiome might help us to better understand the pathology of CRS and might help to develop
      new microbiota-based strategies for CRS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>differences in bacterial communities colonizing the upper respiratory tract between healthy individuals and CRS patients measured via Illumina MiSeq</measure>
    <time_frame>up to 4 years before all samples from both groups are collected and processed</time_frame>
    <description>After Illumina MiSeq sequencing, bio-informatic tools will be used to cluster bacteria into operational taxonomic units (OTUs). Based on these OTUs, we will compare the composition of the bacteria in the sampled niches and compare this composition between healthy individuals and chronic rhinosinusitis patients. We will specifically screen for OTUs that are over- or underrepresented in both populations. Furthermore, special attention will go to screen for the typical nasopharyngeal pathogens such as Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, ... and also to beneficial microbes such as lactic acid bacteria.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Microbiota Upper Respiratory Tract</condition>
  <arm_group>
    <arm_group_label>Control group (healthy)</arm_group_label>
    <description>Participants who do not suffer from acute or chronic airway infections</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CRS patients</arm_group_label>
    <description>Patients who suffer from chronic rhinosinusitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention, compare URT microbiome healthy control group-chronic rhinosinusitis patients</intervention_name>
    <arm_group_label>Control group (healthy)</arm_group_label>
    <arm_group_label>CRS patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population involves both healthy individuals and CRS patients.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Exclusion Criteria healthy population:

          -  no use of antibiotics in the past year

          -  no acute or chronic airway infections

          -  no cancer

          -  no autoimmune diseases

          -  pregnant women

        Exclusion Criteria CRS population:

        --&gt; no exclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <state>Antwerp</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier M Vanderveken, MD, PhD</last_name>
      <phone>+ 32 3 821 33 84</phone>
      <email>Olivier.Vanderveken@uza.be</email>
    </contact>
    <contact_backup>
      <last_name>Ilke De Boeck, MS</last_name>
      <phone>+32 3 265 3217</phone>
      <email>ilke.deboeck@uantwerpen.be</email>
    </contact_backup>
    <investigator>
      <last_name>Olivier M Vanderveken, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2016</study_first_submitted>
  <study_first_submitted_qc>October 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2016</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Antwerp</investigator_affiliation>
    <investigator_full_name>Ethisch Comit√© UZA</investigator_full_name>
    <investigator_title>prof. dr. Olivier Vanderveken, MD, PhD</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

